)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Traws Pharma
Traws Pharma (TRAW) investor relations material
Traws Pharma Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary26 Oct, 2026
Company overview and business model
Clinical-stage biopharma focused on investigational therapies for respiratory viral diseases, targeting difficult-to-treat or resistant strains with simple dosing regimens and accelerated trial strategies.
Four clinical programs: tivoxavir marboxil for influenza, ratutrelvir for COVID-19, and oncology candidates narazaciclib and rigosertib.
Business focus expanded from cancer drug development after the April 2024 merger with Trawsfynydd Therapeutics, adding antiviral development for influenza, COVID-19 and other infectious diseases.
Financial performance and metrics
KPMG’s audit report on FY2025 and FY2024 consolidated statements includes an explanatory paragraph citing recurring operating losses since inception and substantial doubt about ability to continue as a going concern.
Use of proceeds and capital allocation
No proceeds from Roth Principal Investments’ resales; up to $50M gross may be received from stock sales under the purchase agreement, with estimated net proceeds up to ~$46.5M if the full commitment is sold.
Intended uses are product-candidate development, working capital and general corporate purposes; proceeds depend on sale frequency and prices, and no shares may be issued.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Traws Pharma
- Shareholders face a discretionary 1-for-8 to 1-for-15 reverse-split vote.TRAW
Proxy filing - A reverse-split vote is central to efforts to retain Nasdaq listing compliance.TRAWProxy filing
- A discretionary 1-for-8 to 1-for-15 split is proposed to address Nasdaq listing compliance.TRAWProxy filing
- Net loss widened, cash is limited, and milestone-based financing was secured.TRAWQ2 2026
- All proposals passed, including director elections and incentive plan changes; no questions raised.TRAWAGM 2026
- Registering up to $139.2M in securities to fund antiviral and oncology R&D amid financial uncertainty.TRAWRegistration filing
- Annual meeting seeks approval for director elections, incentive plan changes, and warrant issuances.TRAWProxy filing
- Shareholders will vote on directors, plan amendments, auditor ratification, and warrant share issuance.TRAWProxy filing
- Lead antivirals progress, $20M financing, and CEO change position for 2025 milestones.TRAWQ4 2024 & Study Update
Next Traws Pharma earnings date
Q3 202620 Nov, 2026
Traws Pharma
Next Traws Pharma earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Traws Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for respiratory viral diseases and cancer. The company focuses on creating novel treatments for conditions such as influenza, COVID-19, and various cancers, utilizing advanced drug development technologies including artificial intelligence and machine learning. The company is headquartered in Newtown, Pennsylvania, and its shares are listed on NASDAQ.